- Home
- XPEL vs SPRY Comparison
XPEL vs SPRY Comparison
Compare XPEL & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XPEL | SPRY |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 558.9M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | XPEL | SPRY |
|---|---|---|
| Price | $48.76 | $5.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $56.00 | $40.00 |
| AVG Volume (30 Days) | 146.8K | ★ 1.5M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.12 | N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | ★ $476,200,000.00 | $84,278,000.00 |
| Revenue This Year | $12.64 | $87.40 |
| Revenue Next Year | $11.98 | $81.64 |
| P/E Ratio | $48.47 | ★ N/A |
| Revenue Growth | ★ 13.27 | N/A |
| 52 Week Low | $31.50 | $4.91 |
| 52 Week High | $55.91 | $13.15 |
Technical Indicators
Market Signals| Indicator | XPEL | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 48.41 | 38.17 |
| Support Level | $48.53 | $5.04 |
| Resistance Level | $49.41 | $8.61 |
| Average True Range (ATR) | 1.36 | 0.31 |
| MACD | -0.25 | -0.00 |
| Stochastic Oscillator | 18.51 | 9.57 |
Price Performance
Historical ComparisonAbout XPEL XPEL Inc.
XPEL Inc is a supplier of protective films, coatings, and related services principally to the automobile aftermarket, new car dealerships, and automobile original equipment manufacturers, or OEMs. The majority of its revenue is derived from Product, which includes Paint protection film and Window film. The company derives revenue from Service, which includes Software, Cutbank credits, and Installation labor. The majority of revenue is derived from the United States.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.